AbbVie Should Consider a Dividend Cut -- Here's Why
Since its split from Abbott Laboratories in 2013, (NYSE: ABBV) has been the third best-performing stock in terms of total returns on capital (assuming the dividend was reinvested) on the esteemed list of dividend Kings. These special companies have raised their dividends for at least 50 years, and AbbVie inherited this status from its former parent company Abbott.
AbbVie's top-shelf performance has been due to two main factors. First up, the company successfully expanded Humira's label at a breakneck pace over this period, transforming it into the world's first pharma product to exceed $20 billion a year in sales.
Image source: Getty Images.
Source Fool.com
AbbVie Inc. Stock
€173.94
-0.680%
The stock is an absolute favorite of our community with 32 Buy predictions and no Sell predictions.
As a result the target price of 180 € shows a slightly positive potential of 3.48% compared to the current price of 173.94 € for AbbVie Inc..
